Clinical trials: Moderate to Severe Chronic Pain
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.
Pain
A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
To show, using the analgesic WHO scale, that fentanyl-TTS may be directly used for treating moderate to severe cancer pain in patients treated with NSAIDs, acetaminophen, or metamizole (first step drugs) avoiding the second step…
- Trial name
- NCT00576017
- Testing
- Fentanyl-TTS
- Volunteers
- 19 people
- Sponsor
- Janssen-Cilag, S.A.
Low Back Pain
Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
The primary objective of this study is to assess the efficacy and safety of OXN compared to placebo in opioid-experienced subjects with moderate to severe pain due to chronic low back pain who require around-the-clock opioid…
- Trial name
- NCT01358526
- Testing
- Oxycodone/Naloxone Controlled-release
- Where
- 151 sites in United States
- Volunteers
- 1,095 people
- Sponsor
- Purdue Pharma LP
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.
The purpose of this study is to assess the safety of tramadol HCl ER following long-term treatment. The study hypothesis is that long-term treatment with tramadol HCl ER is safe and effective for the treatment of chronic…
- Trial name
- NCT00347685
- Testing
- tramadol ER
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Pain
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by…
- Trial name
- NCT01240863
- Testing
- Hydrocodone ER
- Where
- 73 sites in United States
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Low Back Pain
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate…
- Trial name
- NCT00449176
- Testing
- tapentadol (CG5503) ER, oxycodone CR
- Volunteers
- 981 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Moderate to Severe Chronic, Non-malignant Pain
Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain
The purpose of the study is to evaluate the safety of Vicodin CR (combination opioid and acetaminophen containing product) in patients with chronic pain due to osteoarthritis or low back pain.
- Trial name
- NCT00195728
- Testing
- Hydrocodone/Acetaminophen on Extended Release
- Where
- 76 sites in United States
- Volunteers
- 431 people
- Sponsor
- Abbott
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Knee Osteoarthritis
Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.
This is a phase 3, multicentre, prospective, single-blind on principal efficacy criterion, 2 parallel groups, randomized, controlled clinical study comparing efficacy and safety of actiTENS versus systemic level 2 analgesics…
- Trial name
- ArthroTENS (NCT03902340)
- Testing
- ActiTENS, Level 2 Analgesic Treatments
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Sublimed
Osteoarthritis, Osteoarthritis, Knee
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
- Conditions
- Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia
- Trial name
- NCT01094262
- Testing
- Oxycodone CR (standard pain medication), JNJ-42160443
- Where
- 44 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Lower Back Pain, Chronic Pain
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that…
- Trial name
- CAM2038 (NCT02946073)
- Testing
- buprenorphine
- Where
- 69 sites in United States
- Volunteers
- 1,053 people
- Sponsor
- Braeburn Pharmaceuticals
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee.
- Trial name
- NCT01709214
- Testing
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Oxycodone CR
- Where
- 83 sites in United States
- Volunteers
- 619 people
- Sponsor
- Tris Pharma, Inc.
Chronic Low Back Pain
Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their…
- Trial name
- NCT01452529
- Testing
- Hydrocodone bitartrate q24h film-coated tablets
- Where
- 102 sites in United States
- Volunteers
- 905 people
- Sponsor
- Purdue Pharma LP
Moderate-to-severe Chronic Noncancer Pain
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
- Trial name
- NCT02603705
- Testing
- Oxycodone extended-release
- Where
- 39 sites in United States
- Volunteers
- 281 people
- Sponsor
- Egalet Ltd
Pain, Chronic Back Pain
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain (LBP) or osteoarthritis (OA) of the hip or…
- Conditions
- Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
- Trial name
- NCT01631513
- Testing
- Nucynta ER
- Where
- 7 sites in United States
- Sponsor
- Janssen Scientific Affairs, LLC
Osteoarthritis, Knee
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
This is a randomized, double-blind, placebo-controlled, 2-injection, 52-week study to evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects with chronic, moderate-to-severe osteoarthritis knee…
- Trial name
- NCT03660943
- Testing
- CNTX-4975-05
- Where
- 30 sites in United States
- Volunteers
- 332 people
- Sponsor
- Centrexion Therapeutics
Back Pain Lower Back Chronic
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01125917
- Testing
- Buprenorphine transdermal patch
- Where
- 84 sites in United States
- Volunteers
- 354 people
- Sponsor
- Purdue Pharma LP
Anal Fissure
Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure
RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US Food and Drug Administration (FDA) for adults.
- Trial name
- NCT01920074
- Testing
- Nitroglycerin Ointment 0.4%
- Where
- 6 sites in United States
- Sponsor
- Forest Laboratories
Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
- Trial name
- NCT00415597
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Where
- 58 sites in United States
- Volunteers
- 467 people
- Sponsor
- Pfizer